EUROPEAN
COMMISSION

Brussels, XXX
PLAN/74/2024 ANNEX
(POOL/G2/2024/PLAN_74/2024-EN ANNEX.docx)
[…](2022) XXX draft

ANNEX

ANNEXES

to the

COMMISSION DELEGATED REGULATION

amending and correcting Delegated Regulation (EU) 2020/692 supplementing Regulation (EU) 2016/429 of the European Parliament and of the Council as regards rules for entry into the Union, and the movement and handling after entry of consignments of certain animals, germinal products and products of animal origin

EN

ANNEX

PART A

Annexes VI, VIII, XIII and XXI to Delegated Regulation (EU) 2020/692 are amended as follows:

(1) in Annex VI, the following PART C is added:

'**PART C**

SPECIFIC CONDITIONS FOR THE ENTRY INTO THE UNION OF UNGULATES AS REGARDS INFECTION WITH EPIZOOTIC HAEMORRHAGIC DISEASE VIRUS

(AS REFERRED TO IN ARTICLE 23(4))

Where ungulates of listed species do not originate from an establishment in and around which, including when appropriate the territory of a neighbouring country, infection with epizootic haemorrhagic disease virus has not been reported in a radius of 150 km in the two years prior to the date of dispatch of the consignment, they must originate from an establishment which complies with at least one of the following requirements:

(a) the animals have been kept in a zone seasonally free from infection with epizootic haemorrhagic disease virus as defined in Part 1 and Part 2 of Annex IX to Commission Delegated Regulation (EU) 2020/688:

  (i) for at least 60 days prior to the date of dispatch of the consignment to the Union; or

  (ii) for at least 28 days prior to the date of dispatch of the consignment to the Union, and have undergone a serological test, with negative results, carried out on samples collected at least 28 days following the date of the animal's entry into the zone seasonally free from infection epizootic haemorrhagic disease virus); or

  (iii) for at least 14 days prior to the date of dispatch of the consignment to the Union, and have undergone a polymerase chain reaction (PCR) test, with negative results, carried out on samples collected at least 14 days following the date of the animal's entry into zone that is seasonally free from infection epizootic haemorrhagic disease virus;

(b) the animals originate from a third country or territory, or zone thereof with a surveillance system in place designed and implemented in accordance with Article 3, point 1(a), of Delegated Regulation (EU) 2020/689 and have been vaccinated against infection with epizootic haemorrhagic disease virus and the animals are still within the immunity period guaranteed in the specifications of the vaccine and the animals comply with at least one of the following requirements:

  (i) they have been vaccinated more than 60 days prior to the date of dispatch of the consignment to the Union; or

(ii) they have been vaccinated with an inactivated vaccine and have undergone a PCR test, with negative results on samples collected at least 14 days after the onset of the immunity protection set out in the specifications of the vaccine.';

(2) Annex VIII is amended as follows:

(a) in point 1, the row for infection with epizootic haemorrhagic disease is replaced by the following:

'Infection with epizootic haemorrhagic disease	150 km/2 years	150 km/2 years	150 km/2 years	NA	150 km/2 years	150 km/2 years	150 km/2 years';

(b) in point 1, the row with the footnotes is replaced by the following:

'only applicable for listed species in accordance with the Annex to Commission Implementing Regulation (EU) 2018/1882 NA = not applicable.';

(3) Annex XIII, point 1 is replaced by the following:

'**1. MINIMUM REQUIREMENTS FOR VACCINATION PROGRAMMES CARRIED OUT IN A THIRD COUNTRY OR TERRITORY OR ZONE THEREOF**

Vaccination programmes against highly pathogenic avian influenza submitted by a third country or territory must include at least the following information:

(1) objectives of the vaccination strategy, selected bird population(s) and area;

(2) data on the epidemiological evolution of the disease, including previous outbreaks in poultry or wild birds;

(3) description of the reasons for the decision to introduce the vaccination;

(4) risk assessment based on:

- highly pathogenic avian influenza outbreaks within that third country or territory or zone thereof,
- highly pathogenic avian influenza outbreak in a neighbouring country,
- other risk factors such as certain areas, type of poultry husbandry or categories of poultry or captive birds;

(5) geographical area where vaccination is carried out;

(6) number of establishments in vaccination area;

(7) number of establishments where vaccination is carried out, if different from the number in point 6;

(8) categories of animals exempted from vaccination and reasoning;

(9) species and categories of poultry or captive birds in the geographical area where vaccination is carried out;

(10) approximate number of poultry or captive birds in the establishments referred to in point 7;

(11) summary of the vaccine characteristics, including the name of the product(s) and the name of the manufacturer(s), and routes of administration, authorisation and quality control; (vaccines containing live avian influenza virus, whether attenuated or not, shall not be used);

(12) handling, storage, supply, distribution and sale of avian influenza vaccines on the national territory;

(13) implementation of a Differentiating Infected from Vaccinated Animals (DIVA) strategy;

(14) envisaged duration of vaccination campaign;

(15) intended final use of vaccinated animals and products;

(16) provisions and restrictions on movements of vaccinated poultry and poultry products derived from vaccinated poultry or vaccinated captive birds;

(17) clinical and laboratory tests, such as efficacy and pre-movement testing, carried out in the establishments vaccinated or located in the vaccination area;

(18) the record keeping system on the vaccination.';

(4) in Annex XXI, point 2(c)(i) is replaced by the following:

'(i) the individual identification number as displayed on the electronic transponder or the tattoo of the dog, cat or ferret;';

PART B

In Annex IV to Delegated Regulation (EU) 2020/692, the row for infection with *Burkholderia mallei* (Glanders) in the table in Part B of Annex IV is replaced by the following:

'Infection with *Burkholderia mallei* (Glanders)	(a) the disease not reported in the establishment of origin during at least 6 months prior to the date of dispatch to the Union; (b) the Commission has recognised the surveillance programme carried out to demonstrate absence of infection in the establishment of origin during that period of 6 months.'

.